Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

MeSH terms

• Humans
• Imidazoles
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
• Protein Kinase Inhibitors / therapeutic use
• Pyridazines*